Although Amicus believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions there can be no assurance that its expectations will be realized. Actual results could differ materially from those projected in Amicus’ forward-looking statements due to numerous known and unknown risks and uncertainties including the risk factors described in our annual report on Form 10(k) for the year ended December 31, 2011. All forward-looking statements are qualified in their entirety by this cautionary statement and Amicus undertakes no obligation to revise or update this presentation to reflect events or circumstances after the date hereof.
At this time it is my pleasure to turn the call over to John Crowley, Chairman and Chief Executive Officer of Amicus.
Great, thank you Sara, and good evening everybody and thanks for joining. This is very, very good news that we’re happy to announce this evening. As Sara indicated I’m joined by a number of members of the Executive Team here at Amicus, and before I turn it over to Brad and David in particular to take us through a number of different slides that hopefully everybody has now available to them – and we’ll reference those throughout this presentation – let me just reiterate why this is such a significant deal for Amicus and for continued collaboration and strengthening of that collaboration with GSK.Again, three major components to this transaction: first is the agreement that we will jointly develop with our partners at GSK a next generation proprietary enzyme replacement therapy in Fabry disease that co-formulates and utilizes our core platform technology – the use of the chaperone migalastat; so a proprietary ERT developed by GSK, and we’ll talk more about the history of that development here and how it came to be and the significance of that ERT now combined. So a propriety co-formulated ERT that’s been in development for some time.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV